Smith & Nephew plc (SN) Given New GBX 1,369 Price Target at J P Morgan Chase & Co
Smith & Nephew plc (LON:SN) had its price target lowered by J P Morgan Chase & Co from GBX 1,382 ($18.18) to GBX 1,369 ($18.01) in a research report report published on Monday. The brokerage currently has a neutral rating on the stock.
SN has been the topic of a number of other research reports. Deutsche Bank AG reaffirmed a buy rating on shares of Smith & Nephew plc in a report on Friday, October 13th. Jefferies Group LLC reaffirmed a buy rating and issued a GBX 1,515 ($19.93) price objective on shares of Smith & Nephew plc in a report on Thursday, October 12th. Credit Suisse Group reaffirmed a neutral rating and issued a GBX 1,280 ($16.84) price objective on shares of Smith & Nephew plc in a report on Friday, July 28th. Citigroup Inc. reaffirmed a sell rating and issued a GBX 1,160 ($15.26) price objective on shares of Smith & Nephew plc in a report on Thursday, October 12th. Finally, Berenberg Bank reaffirmed a hold rating and issued a GBX 1,300 ($17.10) price objective on shares of Smith & Nephew plc in a report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of GBX 1,302.83 ($17.14).
Shares of Smith & Nephew plc (SN) traded up GBX 7 ($0.09) during trading hours on Monday, hitting GBX 1,339 ($17.61). 2,283,258 shares of the company’s stock were exchanged, compared to its average volume of 3,640,000. Smith & Nephew plc has a 52 week low of GBX 1,064.91 ($14.01) and a 52 week high of GBX 1,442 ($18.97).
In related news, insider Virginia Bottomley bought 223 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average price of GBX 1,380 ($18.15) per share, for a total transaction of £3,077.40 ($4,047.61).
Smith & Nephew plc Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.